To see the presentations you must be registered and logged in with your user


Mycetoma, a globally neglected disease, exacts a heavy toll on the most vulnerable populations residing
in impoverished, remote, and underprivileged communities. Its prevalence in these regions underscores
the stark reality that mycetoma primarily afflicts the poorest of the poor. The consequences of this
insidious ailment extend far beyond the confines of individual health, inflicting serious and devastating
medical and socio-economic impacts on patients, their families, entire communities, and the already
strained health systems within endemic regions. The burden of mycetoma is not merely confined to
physical suffering; it permeates every facet of life in these marginalised areas. Patients grappling with
mycetoma not only endure the pain and debilitation wrought by the disease but also face social stigma,
diminished economic opportunities, and a heightened susceptibility to further health disparities. The
long-lasting effects ripple through families, impairing their ability to thrive, perpetuating a cycle of
poverty, and exacerbating the existing challenges faced by communities already grappling with limited
resources. The repercussions extend to the broader health infrastructure, placing additional strain on
already overburdened systems in regions where mycetoma is endemic. In essence, mycetoma’s
profound impact underscores the urgent need for increased attention, resources, and concerted efforts
to address the unique challenges posed by this neglected disease and alleviate the suffering of those
who bear its brunt in the world’s most underserved communities. With limited treatment options
available, there is a pressing need for novel therapeutic interventions. However, pharmaceutical
companies have shown reluctance to invest in discovering mycetoma drugs.

Mycetoma, NTDs, management, awareness